Catalyst Biosciences, Inc. (CBIO)
(Delayed Data from NSDQ)
$8.46 USD
+0.26 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Gyre Therapeutics, Inc. [CBIO]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Termination of Coverage
Provider: Rodman & Renshaw, Co.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Factor IX Preclinical Data at ASH 2016; Reiterate Buy and Adjusting Price Target to $2
Provider: H.C. Wainwright & Co., Inc.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Factor IX Preclinical Data at ASH 2016; Reiterate Buy and Adjusting Price Target to $2
Provider: Rodman & Renshaw, Co.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Prophylactic Subcutaneous Factor IX and Factor VIIa to Enter Clinical Trials in 2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Prophylactic Subcutaneous Factor IX and Factor VIIa to Enter Clinical Trials in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Canceling Out Clotting Disorders; Initiating at Buy with $3.50 Price Target
Provider: Rodman & Renshaw, Co.
Company: Gyre Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Canceling Out Clotting Disorders; Initiating at Buy with $3.50 Price Target
Provider: H.C. Wainwright & Co., Inc.
|